ORG
AstraZeneca’s oral PCSK9 inhibitor halves cholesterol in phase 2 trial
AZD0780, LDL Cholesterol Lipoproteins, AstraZeneca ‘s, Oral cavity, PCSK9 inhibitor, Effectiveness
Merck’s Winrevair Slashes Morbidity and Mortality Risk in Pulmonary Arterial Hypertension
Winrevair, pulmonary arterial hypertension (PAH), Phase III ZENITH trial, morbidity, mortality, Merck
Solbinsiran Demonstrates Significant Lipid Reductions in Phase 2 Trial for Mixed Dyslipidemia
Solbinsiran, siRNA, mixed dyslipidemia, Eli Lilly, PROLONG-ANG3, apolipoprotein B, LDL-C, triglycerides
Isomorphic Labs raises $600M to push AI-designed drugs into clinic
Isomorphous, Laboratory test finding, development aspects, AI-designed
ACC25: Merck & Co.’s Winrevair reduces mortality in most severe PAH patients
Pulmonary arterial hypertension, Winrevair, Severe (severity modifier), Mortality Vital Statistics
Transcend’s neuroplastogen posts positive mid-stage results in PTSD
TSND-201, Post-Traumatic Stress Disorder, Placebos, Statistical Significance, CAPS-5
Corcept planning US, EU submissions for cortisol modulator after ovarian cancer win
Corcept, 130-nm albumin-bound paclitaxel
BiomX’s phage therapy shows promise in Phase II diabetic foot infections study
BX211, Phage Therapy, DFO
Bluebird bio receives rival M&A bid worth 50% higher than Carlyle-SK offer
Ayrmid, Family Turdidae (organism), Twice a day, gene therapy, Carlyle, High, Bluebird Bio, Capital
Biotech Restructuring and European Regulatory Setbacks
LifeMine Therapeutics, layoffs, PTC Therapeutics, Translarna, Duchenne muscular dystrophy, European Commission, regulatory decision